News
AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback